Biohaven Showcases Promising BHV-1530 Data at EORTC-NCI-AACR Symposium 2026

Biohaven Ltd. is excited to announce that new clinical data on its innovative drug, BHV-1530, has been selected for an oral presentation at the prestigious 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, scheduled from November 18 to 20, 2026, in Barcelona, Spain. This symposium is considered a leading international forum for the development of early-phase oncology drugs, making this selection a significant milestone for Biohaven.

BHV-1530 is a first-in-class antibody-drug conjugate (ADC) specifically designed to target FGFR3, a critical player in several cancers, particularly urothelial carcinoma. The ADC utilizes Biohaven's proprietary Topoisomerase I (TopoIx) payload, which has shown promising early clinical activity in treating advanced tumors. Recent data highlights that BHV-1530 not only demonstrates a differentiated safety profile but also shows potential efficacy even in heavily pre-treated patients.

Presentation Highlights

During the upcoming oral presentation, titled "Phase 1 study of BHV-1530, a first-in-class FGFR3 ADC in Advanced Tumors," Biohaven will share crucial insights from the ongoing BHV1530-101 study. This study is a comprehensive Phase 1, open-label, multicenter trial that aims to evaluate BHV-1530 both as a standalone treatment and in combination with cemiplimab (Libtayo), a PD-1 inhibitor, across various advanced solid tumors.

The session is set for November 19, 2026, at 10:00 AM, and promises to provide detailed findings regarding the safety and efficacy of BHV-1530, emphasizing its potential benefits in patients with FGFR3 alterations. Early indicators from the trial have revealed no dose-limiting toxicities and a favorable safety profile devoid of common class-related adverse effects seen with other FGFR inhibitors.

Collaboration with Regeneron

In an exciting development, Biohaven has entered into a clinical supply agreement with Regeneron Pharmaceuticals to investigate the combination of BHV-1530 with cemiplimab. Early preclinical data suggests a synergistic effect between these two therapies, supporting the potential for enhanced efficacy against solid tumors. Enrollment for this combination cohort has already commenced, further leveraging Biohaven’s commitment to exploring innovative treatment options in oncology.

Numerous FGFR3-driven tumors remain inadequately treated with current therapies, particularly those that do not meet specific genomic selection criteria for existing FGFR tyrosine kinase inhibitors. BHV-1530 is positioned to address this gap, providing a treatment avenue for patients regardless of FGFR3 genetic status, thus broadening the therapeutic landscape for difficult-to-treat cancers.

Future Perspectives

Biohaven’s investigational drug development reflects a strategic focus on harnessing novel molecular pathways to treat cancers characterized by FGFR3 overexpression or mutations. The forthcoming presentation at EORTC-NCI-AACR will not only shed light on the pivotal findings of the BHV-1530 study but also reaffirm Biohaven’s leading role in identifying and bringing to market life-changing therapies in serious diseases.

In conclusion, Biohaven continues to progress steadily towards its mission of revolutionizing cancer treatment through innovative research and collaborations. The outcomes of the BHV1530-101 study have the potential to be a game-changer in the fight against FGFR3-related malignancies, offering hope to patients in need and further grounding Biohaven's position in the oncology field. Stay tuned for more updates as this unfolding story develops in the coming months.